Date: Thu, 18 Dec 1997 17:51:20 GMT
Server: Apache/1.2.4
Last-Modified: Thu, 30 Oct 1997 19:29:04 GMT
ETag: "9770-5c38-3458e000"
Content-Length: 23608
Accept-Ranges: bytes
Connection: close
Content-Type: text/html

<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta name="GENERATOR" content="Microsoft FrontPage 3.0">
<title>AVIGEN Home Page</title>

<meta name="Microsoft Border" content="none, default"></head>

<body background="images/Background.jpg" bgcolor="#FFFFFF">

<table border="0" width="100">
  <tr>
    <td><img src="images/AvigenLogo1.jpg" width="512" height="100"></td>
  </tr>
  <tr>
    <td><table border="0" width="100">
      <tr>
        <td><img src="images/aav_rotating_complex.gif" width="65" height="65"></td>
        <td valign="top"><img src="images/AvigenLogo2.gif" width="480" height="100"></td>
      </tr>
    </table>
    </td>
  </tr>
</table>

<p><a href="news.htm" target><img src="images/WhatsNew.gif" alt="News from Avigen" style="border: 0" border="0" width="119" height="36"></a><a href="AAV_Info.htm" target><img src="images/AAV%20Vectors.gif" alt="AAV Vectors" style="border: 0" border="0" width="119" height="36"></a><font size="2" face="MS Sans Serif"> <a href="jobs.htm" target><img src="images/Employment.gif" alt="Employment" style="border: 0" border="0" width="119" height="36"></a> <a href="http://www.nasdaq.com/scripts/quote.dll?symbol=avgn&amp;mode=stock+quote" target><img src="images/Nasdaq.gif" alt="Nasdaq - AVGN" style="border: 0" border="0" width="119" height="36"></a> </font><a href="CorporatePartners.htm" target><img src="images/CorpPartners.gif" alt="Corporate Partners" style="border: 0" border="0" width="119" height="36"></a>&nbsp; <a href="toc.htm" target><img src="images/Contents.gif" alt="Table of Contents" style="border: 0" border="0" width="119" height="36"></a></p>

<p><font size="2" face="MS Sans Serif">Avigen is a publicly held company with its
headquarters in Alameda, California. The company is listed on NASDAQ as <a href="http://www.nasdaq.com/scripts/quote.dll?symbol=avgn&amp;mode=stock+quote"><strong>AVGN</strong></a>.
Avigen is a leader in the development of <a href="gene_therapy.htm"><strong>gene therapy</strong></a>
products derived from adeno-associated virus (&quot;AAV&quot;) for the treatment of
inherited and acquired diseases. Our proposed gene therapy products are designed for in
vivo administration to achieve the production of therapeutic proteins within the body. We
are developing two broad-based proprietary gene delivery technologies:<strong> <a href="aav.htm">AAV vectors</strong></a> and the Targeted Vector Integration (&quot;<a href="tvi_system.htm"><strong>TVI</strong></a>&quot;) system. Avigen believes AAV vectors
can be used to deliver genes for the treatment of brain, liver and prostate cancer,
anemia, hemophilia, hyperlipidemia and metabolic storage diseases. We also believe that
our TVI system will allow us to pursue more effective treatments for blood cell-related
diseases, including sickle cell anemia, beta-thalassemia and human immunodeficiency virus
(&quot;HIV&quot;) infection. </font></p>

<hr>

<h2><font color="#FF0000" size="5" face="MS Sans Serif">Our Mission</font></h2>

<p><font size="2" face="MS Sans Serif">To be a leader in the field of Gene Therapy by
developing simple practical approaches to treating major human diseases with our
technologies.</font></p>

<hr>

<h2><font color="#FF0000" size="5" face="MS Sans Serif">Company Profile</font></h2>

<p><font size="3" face="MS Sans Serif"><strong>AAV Vectors</strong>.</font><font size="2" face="MS Sans Serif"> Avigen's gene therapy products are based on gene delivery systems
called vectors. <a href="aav.htm"><strong>AAV vectors</strong></a> are derived from AAV, a
common non-pathogenic human virus, and take advantage of the natural efficiency with which
viruses deliver genes to cells. To produce an AAV vector, the virus is modified by
removing the viral genes and replacing them with genes for therapeutic proteins. We
believe that AAV vectors combine desirable properties of viral and non-viral vectors and
may offer several potential advantages over other gene therapy vectors. These advantages
include efficient delivery of genes to both dividing and non-dividing target cells,
absence of viral genes that may be responsible for causing an undesirable immune response,
in vivo administration to patients, higher levels of gene expression and improved
stability allowing AAV vectors to be manufactured, stored and handled like more
traditional pharmaceutical products. Avigen believes that its proprietary manufacturing
process will simplify manufacturing and purification and achieve increased yield of high
purity AAV vectors. <br>
</font></p>

<p><font size="3" face="MS Sans Serif"><strong>TVI System</strong></font><font size="2" face="MS Sans Serif">. Avigen's proprietary<strong> <a href="tvi_system.htm">TVI system</strong></a>
utilizes components of AAV to integrate large segments of DNA at a specific location on
human chromosome 19. Integration is essential for certain gene therapy applications where
the genes must be passed on to the progeny of the cell. We believe gene therapy vectors
that integrate at a specific site, such as the site on chromosome 19 where the
non-pathogenic AAV normally integrates, will have an increased safety profile relative to
vectors that integrate randomly. We also believe that the ability to integrate large
segments of DNA could lead to gene therapy applications involving the delivery of multiple
genes or requiring precise or controllable gene regulation. <br>
</font></p>

<p><font size="3" face="MS Sans Serif"><strong>Product Development</strong></font><font size="2" face="MS Sans Serif">. Based on encouraging results in animal models, Avigen has
initiated two preclinical development programs using AAV vectors for the treatment of
hemophilia and brain tumors. Additionally, we have a number of research programs and
collaborations intended to generate product development candidates for liver and prostate
cancer, hyperlipidemia, metabolic storage diseases, hemoglobin disorders and HIV
infection. We believe that the number of potential applications for gene therapy will
increase significantly as advances are made in the area of genomics. These advances are
enabling scientists to link diseases to specific gene defects. As more genes are
discovered, the need for improved gene delivery technologies is expected to increase. With
the identification of new disease-related genes, we believe that our AAV vectors and TVI
system will provide significant opportunities for new gene therapy products. <br>
</font></p>

<p><a href="CorporatePartners.htm"><strong><font size="3" face="MS Sans Serif">Corporate
Partnering Opportunities</font><font size="2" face="MS Sans Serif">.</strong></a> Avigen
is actively seeking to develop long-term strategic collaborations with pharmaceutical
companies that can provide funding for research and development activities for potential
products of the sponsor. We also are looking for new applications to disease, and for new
gene sequences to deliver. We and our collaborators have delivered over thirty different
genes, so we can do custom development programs on applications that would fit the product
lines and/or research interests of most pharmaceutical companies.</font></p>

<p><font size="3" face="MS Sans Serif"><strong>Finance History.</strong></font><font size="2" face="MS Sans Serif"> Avigen was established as a private company in October 1992
with a focus on gene therapy. Avigen commenced an initial public offering in May 1996,
raising $20 million on 2.5 million shares. So far, the company has raised a total of $32.9
million in equity financing through public and private sources from U.S. and Japanese
investors. The company is listed on NASDAQ as <a href="http://www.nasdaq.com/scripts/quote.dll?symbol=avgn&amp;mode=Stock+Quote"><strong>AVGN</strong></a>.</font></p>

<hr>

<p><font color="#FF0000" size="5" face="MS Sans Serif"><strong>Product Development
Programs</strong></font><font size="3" face="MS Sans Serif"><br>
</font><font size="2" face="MS Sans Serif">The company has selected its product
development programs based on experimental data that demonstrate the feasibility of gene
delivery to specific target cells. We believe that our technologies may be used with
several different genes, giving rise to multiple product and corporate partnering
opportunities, and that further advances in genomics, including the sequencing, mapping
and identification of genes linked to diseases, may offer other product opportunities. The
following table summarizes Avigen's current product development programs:- </font></p>

<p align="center"><font color="#000000" size="5"><strong>Avigen AAV Vector-Based Gene
Therapy Programs</strong></font></p>
<div align="center"><center>

<table border="6" cellpadding="4" bgcolor="#C0C0C0" bordercolor="#000000" bordercolorlight="#008080">
  <tr>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Program</strong></font></th>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Indication</strong></font></th>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Target
    Cell</strong></font></th>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Status</strong></font></th>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0"><font size="3">Blood
    Diseases</font></td>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0"><font size="3">Hemophilia</font></td>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0"><font size="3">Muscle</font></td>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0"><font color="#FF0000" size="3"><strong>Preclinical</strong></font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0">&nbsp;</td>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0"><a href="anemia.htm"><font size="3">Anemia</font></a></td>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0"><font size="3">Muscle</font></td>
    <td bgcolor="#DDD5A4" bordercolordark="#C0C0C0" bordercolorlight="#C0C0C0"><font size="3">Research</font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Cancer</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><a href="tk_cancer.htm"><font size="3">Brain
    Tumors</font></a></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Tumor</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font color="#FF0000" size="3"><strong>Preclinical</strong></font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0">&nbsp;</td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Liver <a href="cancer.htm">Cancer</font></a></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Tumor</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Research</font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0">&nbsp;</td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Prostate <a href="cancer.htm">Cancer</font></a></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Tumor</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Research</font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Neural Diseases</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Parkinsons Disease</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Brain</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Research</font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Metabolic Diseases</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Hyperlipidemia</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Muscle</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Research</font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0">&nbsp;</td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Storage Diseases</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Muscle</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Research</font></td>
  </tr>
</table>
</center></div>

<p align="left">&nbsp;</p>

<p align="center"><font color="#000000" size="5"><strong>Avigen TVI-Based Gene Therapy
Programs</strong></font></p>
<div align="center"><center>

<table border="6" cellpadding="4" bgcolor="#C0C0C0" bordercolor="#000000" bordercolorlight="#008080">
  <tr>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Program</strong></font></th>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Indication</strong></font></th>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Target
    Cell</strong></font></th>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font color="#000000" size="4"><strong>Status</strong></font></th>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Blood Diseases</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><a href="anemia.htm"><font size="3">Anemia</font></a></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">BoneMarrow</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Research</font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Infectious Diseases</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">HIV</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Bone Marrow</font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="3">Research</font></td>
  </tr>
</table>
</center></div>

<p>&nbsp;</p>

<hr>

<p><font color="#FF0000" size="5" face="MS Sans Serif"><strong>Management</strong></font></p>
<div align="center"><center>

<table border="5" bgcolor="#C0C0C0" bordercolorlight="#008080">
  <tr>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font size="2" face="MS Sans Serif">NAME </font></th>
    <th bgcolor="#008080" bordercolor="#FFFFFF"><font size="2" face="MS Sans Serif">POSITION </font></th>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#Philip J. Whitcome">Philip J. Whitcome, Ph.D.</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Chairman
    of the Board </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#John Monahan">John Monahan, Ph.D.</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">President,
    Chief Executive Officer and Director </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#Thomas J. Paulson">Thomas J. Paulson</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Vice
    President, Finance and Chief Financial Officer </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#Gary J. Kurtzman">Gary J. Kurtzman, M.D.</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Vice
    President, Research and Development </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#Wanda deVlaminck">Wanda deVlaminck</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Vice
    President, Clinical and Regulatory Affairs </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><a href="board.htm#Robert M. Maurer"><font size="2" face="MS Sans Serif">Robert H. Maurer</font></a></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Vice
    President Business Development</font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><a href="board.htm#Zola Horovitz"><font size="2" face="MS Sans Serif">Zola Horovitz, Ph.D. </font></a></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Director </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#Yuichi Iwaki">Yuichi Iwaki, M.D., Ph.D.</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Director </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><a href="board.htm#Richard T. Pratt"><font size="2" face="MS Sans Serif">Richard T. Pratt </font></a></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Director </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#John K.A. Prendergast">John K.A. Prendergast, Ph.D.</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Director </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#Lindsay A. Rosenwald">Lindsay A. Rosenwald, M.D.</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Director </font></td>
  </tr>
  <tr>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif"><a href="board.htm#Leonard P. Shaykin">Leonard P. Shaykin</a> </font></td>
    <td bgcolor="#DDD5A4" bordercolor="#C0C0C0"><font size="2" face="MS Sans Serif">Director </font></td>
  </tr>
</table>
</center></div>

<p>&nbsp;</p>

<hr>

<p><font color="#FF0000" size="5" face="MS Sans Serif"><strong>Scientific Advisory Board</strong></font><font size="4" face="MS Sans Serif"><br>
</font><font size="2" face="MS Sans Serif">The Company has established a <a href="sab.htm"><strong>Scientific
Advisory Board</strong></a>, consisting of experts in the field of medicine, genetics and
molecular biology, which reviews and evaluates the Company's research programs and advises
the Company with respect to technical matters in fields in which the Company is involved.
The members of the Scientific Advisory Board are prominent scholars in their field and, as
a result, may serve as consultants to a wide variety of companies.</font></p>

<hr>

<p><font color="#FF0000" size="5" face="MS Sans Serif"><strong>Employment Opportunities</strong></font><font size="3" face="MS Sans Serif"> </font><font size="4" face="MS Sans Serif"><br>
</font><font size="2" face="MS Sans Serif">We provide exciting <a href="jobs.htm">career
opportunities</a> to creative, highly motivated individuals, and are an equal opportunity
employer. Submit resumes to: Human Resoures, Avigen, Inc., 1201 Harbor Bay Parkway, Suite
1000, Alameda, CA 94502. </font></p>

<hr>

<h2><font color="#FF0000" size="5" face="MS Sans Serif">Contact Information</font></h2>

<dl>
  <dt><font color="#FF0080" size="2" face="MS Sans Serif"><strong>Telephone</strong></font><font size="2" face="MS Sans Serif"> <img src="images/PhoneF1.gif" width="33" height="33"></font></dt>
  <dd><font size="2" face="MS Sans Serif">510-748-7150</font></dd>
  <dt><font color="#FF0080" size="2" face="MS Sans Serif"><strong>FAX <img src="images/fax1a.gif" width="32" height="32"></strong></font></dt>
  <dd><font size="2" face="MS Sans Serif">510-748-7155 </font></dd>
  <dt>&nbsp;</dt>
  <dt><font color="#FF0080" size="2" face="MS Sans Serif"><strong>Postal address</strong></font><font size="2" face="MS Sans Serif"> <img src="images/mailbox.gif" width="29" height="34"></font></dt>
  <dd><font size="2" face="MS Sans Serif">1201 Harbor Bay Pkwy #100</font></dd>
  <dd><font size="2" face="MS Sans Serif">Alameda, CA 94502 USA</font></dd>
  <dt>&nbsp;</dt>
  <dt><font color="#FF0080" size="2" face="MS Sans Serif"><strong>Electronic mail <img src="images/e-mail.gif" width="60" height="30"></strong></font></dt>
  <dd><font size="2" face="MS Sans Serif">CEO: <a href="mailto:monahan@avigen.com">monahan@avigen.com</font></a></dd>
  <dd><font size="2" face="MS Sans Serif">CFO: <a href="mailto:paulson@avigen.com">paulson@avigen.com</a><br>
    VP R&amp;D: <a href="mailto:kurtzman@avigen.com">kurtzman@avigen.com</a><br>
    VP Clinical Affairs &amp; Operations: <a href="mailto:devlaminck@avigen.com">devlaminck@avigen.com</a><br>
    VP Business Development: <a href="mailto:maurer@avigen.com">maurer@avigen.com</font></a></dd>
  <dd>&nbsp;</dd>
  <dd><font size="1" face="MS Sans Serif">Webmaster: <small><a href="mailto:monahan@avigen.com">monahan@avigen.com</font></a></small></dd>
</dl>
<!--webbot bot="Include" tag="BODY" u-include="_private/navbar.htm" startspan -->

<p><a href="index.htm"><img src="images/HomePage.gif" alt="HomePage" style="border: 0" border="0" width="119" height="36"></a><a href="news.htm" target><img src="images/WhatsNew.gif" alt="WhatsNew" style="border: 0" border="0" width="119" height="36"></a><a href="AAV_Info.htm" target><img src="images/AAV%20Vectors.gif" alt="AAV Vectors" style="border: 0" border="0" width="119" height="36"></a><a href="http://www.nasdaq.com/scripts/quote.dll?symbol=avgn&amp;mode=stock+quote" target><img src="images/Nasdaq.gif" alt="Nasdaq-AVGN" style="border: 0" border="0" width="119" height="36"></a><a href="jobs.htm" target><img src="images/Employment.gif" alt="Employment" style="border: 0" border="0" width="119" height="36"></a><a href="CorporatePartners.htm" target><img src="images/CorpPartners.gif" alt="Corporate Partners" style="border: 0" border="0" width="119" height="36"></a><a href="toc.htm" target><img src="images/Contents.gif" alt="Table of Contents" style="border: 0" border="0" width="119" height="36"></a></p>
<!--webbot bot="Include" endspan i-checksum="34220" -->


<h5><font color="#000000" size="2" face="MS Sans Serif">Please</font><font color="#808080" size="2" face="MS Sans Serif"> </font><font color="#000000" size="2" face="MS Sans Serif">enter
our</font><font color="#808080" size="3" face="MS Sans Serif"> </font><a href="book.htm"><font color="#0000FF" size="3" face="MS Sans Serif">Guestbook.</font></a><font color="#0000FF" size="2" face="MS Sans Serif"> </font><font face="MS Sans Serif">You are visitor number </font><img src="http://www.avigen.com/cgi-bin/Count.cgi?ft=9|frgb=0;0;255|tr=0|trgb=0;0;0|wxh=15;20|md=6|dd=C|st=1|sh=1|df=avigen.count" align="middle" width="108" height="38"> </h5>

<h5><font color="#808080" size="1" face="MS Sans Serif">Last modified: <!--webbot bot="TimeStamp" s-type="EDITED" s-format="%B %d, %Y" startspan -->October 29, 1997<!--webbot bot="TimeStamp" endspan i-checksum="31713" --> </font></h5>

<p><font color="#808080" size="1" face="MS Sans Serif"><img src="images/looker.gif" width="814" height="12"></font></p>
</body>
</html>
